Gilead Sciences, Inc. vs Arrowhead Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown

Gilead Sciences vs. Arrowhead Pharmaceuticals: A Decade of Gross Profit Performance

In the competitive landscape of biotechnology, Gilead Sciences, Inc. and Arrowhead Pharmaceuticals, Inc. have showcased contrasting trajectories in gross profit over the past decade. From 2014 to 2023, Gilead Sciences consistently demonstrated robust financial health, with gross profits peaking in 2015 at approximately $28.6 billion. Despite a slight decline, Gilead maintained an average annual gross profit of around $21.6 billion, underscoring its market dominance.

Conversely, Arrowhead Pharmaceuticals, a smaller player, exhibited a remarkable growth trajectory. Starting with a modest gross profit of $175,000 in 2014, Arrowhead's profits surged, reaching over $240 million by 2023. This represents an impressive growth rate, highlighting Arrowhead's potential in the biotech sector.

While Gilead's figures dwarf those of Arrowhead, the latter's growth story is a testament to its strategic advancements and market adaptability. Missing data for 2024 suggests ongoing developments worth watching.